RespireRx Pharmaceuticals Inc (RSPI)

[myostrain]

That last statement Roger made is interesting. Hope to initiate tox testing of one of the two high impact analogs by year end.
Would that be considered the same as IND-enabling studies-late stage vs. an early stage study?
Would the lack of stating CX1837 be considered as a possible drop of that compound, it would seem illogical to state whats going on with CX1739 and CX1942 and not specifically state CX1837 on its progress.
Over the past few years, regarding the high impact compounds it almost seems warrented to give no weight of any high impact compounds until one actually starts a PH1.
Hoping I am not seeing a subtle drop of the high impact farthest along.